Radiopharm Theranostics
- Country
- Ownership
- -
- Employees
- -
- Market Cap
- -
- Introduction
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
News
Radiopharm Theranostics Appoints Leading Prostate Cancer Expert Dr. Oliver Sartor to Scientific Advisory Board
Radiopharm Theranostics has appointed Dr. Oliver Sartor, an internationally recognized medical oncologist specializing in prostate cancer and radiopharmaceutical therapies, to its Scientific Advisory Board.
Radiopharm Theranostics Advances Phase 1 Trial of PD-L1 Targeting Radiotherapeutic for Advanced Cancers
Data Safety Monitoring Committee has approved continuation of Radiopharm's Phase 1 trial for 177Lu-RAD204, allowing progression to a higher dose cohort without protocol modifications.
Radiopharm's Novel Brain Metastases Imaging Agent Shows 100% Detection Rate in Clinical Study
Radiopharm Theranostics' imaging molecule RAD 101 successfully detected brain metastases in all 22 patients during an observational trial, including both treatment-naïve and previously treated individuals.
Radiopharm and Lantheus Form Strategic Partnership for Radiopharmaceutical Development in Australia
Radiopharm Theranostics has entered into a strategic partnership with Lantheus to advance radiopharmaceutical development in Australia, with an initial focus on a Phase 1 imaging trial for multiple solid tumors. The collaboration includes up to USD 2 million in milestone payments for Radiopharm, with Lantheus covering all clinical development costs.
Radiopharm Theranostics' RAD 202 Receives Ethics Approval for Phase 1 Trial in HER2-Expressing Solid Tumors
Radiopharm Theranostics has received ethics approval in Australia to begin a Phase 1 trial of 177Lu-RAD202 in HER2-expressing solid tumors.
Radiopharm's BetaBart Advances Towards FDA Approval for Cancer Trials
Radiopharm Theranostics is nearing FDA approval for its BetaBart radiotherapeutic agent, targeting the B7-H3 protein in tumors.